THE HUMAN ADVANTAGE

I N

L A B O R A T O R Y

RIGHT DRUG

T E S T I N G

RIGHT DOSE

P H ARMAC OGENETICS

RIGHT TIME

PHARMACOGENETIC
TESTING ADVANTAGE

Personalized MEDICINE

Traditional medicine has employed more of a trial and

error approach in a one-size-fits-all environment.
Pharmacogenetic testing provides physicians with
their patients genotype to determine how each
patient personally metabolizes and responds to
specific medications.
Advancements in genetics now allows physicians to
facilitate genetically tailored treatment plans specific to a
patients personal metabolic profile.

* Belle DJ and Singh H. Genetic Factors in Drug Metabolism. Am Fam Physician. 2008 Jun 1; 77(11);1553-1560.

GENETICS CAN
ACCOUNT FOR 20-95%

OF THE VARIABILITY
IN AN INDIVIDUALS

RESPONSE TO DRUGS.*

The TEST

PHARMACOGENETIC
TESTING ADVANTAGE

Advantas painless, non-invasive DNA specimen collection process is CLIA

compliant, validated, and approved. Pharmacogenetic tests are covered by
Medicare as well as most major commercial insurance carriers.
We simply speed up the process with improved accuracy for medication
treatment so that your patients can return to the activity they love.

ADVANTAGES of DNA Testing:

Minimize side effects and/or

unnecessary drug complications

Reduce adverse drug events and
treatment failures
Improve personalized care - and
clinical outcomes
Decrease the length of stay time
Increase patient quality care
Provides a layer of complience

PHARMACOGENETIC
TESTING ADVANTAGE

Adverse Drug SOLUTION

ADVERSE DRUG EVENTS
ADVERSE DRUG REACTIONS

2.2 MILLION
SEVERE ADVERSE

MEDICATION ERRORS

DRUG EVENTS (ADES)

OCCUR IN THE U.S.

EVERY YEAR.*
A medication error is defined as inappropriate use of a drug that may or may not
result in harm. Such errors may occur during prescribing, transcribing, dispensing,
administering, adherence, or monitoring of a drug. In contrast, an adverse drug
reaction (ADR) is harm directly caused by a drug at normal doses.*
Among older adults (65 years of age or older), 5759 % reported taking
5 to 9 medications.1719 % reported taking 10 or more over the course
of that year.
As many as 33% of all potentially clinically significant drug interactions, one
of the possible causes of ADEs, are caused by drug-gene and drug-drug-gene
interactions and may be missed by drug-drug interaction analysis alone.

*U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. (2014). National Action Plan for Adverse Drug Event Prevention. Washington, DC: Author. Pg: 5

The LIFELINE

PHARMACOGENETIC
TESTING ADVANTAGE

According to the U.S. Food and Drug Administration:

Pharmacogenomics can play an important role in identifying responders
and non-responders to medications, avoiding adverse events, and
optimizing drug dose. Drug labeling may contain information on genomic
biomarkers and can describe:

Drug exposure and clinical response variability

Risk for adverse events
Genotype-specific dosing
Mechanisms of drug action
Polymorphic drug target and disposition genes

PHARMACOGENETIC
TESTING ADVANTAGE

The SIGNIFICANCE

Pharmacogenetic testing is especially significant for people:

Over the age of 65

Taking multiple medications
Who experience (more than typical or atypical) drug side effects
Taking (one or multiple) FDA approved medications with Pharmacogenetic
information in their labels
Who are not responding to medications or prescription medication programs
People under consideration for a prescription medication program (for general
practice, post-surgical treatment and/or disease management)
Taking complex medication(s) that may inhibit these enzymes in practice
Over-medicated falls in the elderly

The FACTS

PHARMACOGENETIC
TESTING ADVANTAGE

With Advanta PGx Test, you treat your patients with the right dose, the right drug,
at the right time greatly eliminating the one size fits all approach to traditional medicine.

Comprehensive PGX Panel Used For:

Cardiology
Internal Medicine
Oncology
Pain Management
Pediatrics
Primary Care
Psychiatry

75%

ROUGHLY 75%
OF THE U.S. P
 OPULATION
DOES NOT METABOLIZE

MEDICATIONS NORMALLY.*

* Villagra D, Goethe J, Schwartz HI, Szarek B, Kocherla M, Gorowski K, et al. Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9,
CYP2C19 and CYP2D6 genes. Biomarkers in medicine. 2011;5(4):427-38. Epub 2011/08/25. doi: 10.2217/bmm.11.32. PubMed PMID: 21861665; PubMed Central PMCID: PMC3225004.

PHARMACOGENETIC The Assay PANELS

TESTING ADVANTAGE
Our genetics laboratroy assesses enzymes (of the Cytochrome P450 System),
CYP 2D6, 2C9, and 2C19. These enzymes are relied upon by over 50% of all
medications routinely prescribed including cardiovascular medication (i.e. Plavix,
Warfarin, ARBs, Beta/Calcium Channel blockers, Antiarrhythmic, etc.), pain
medications, NSAIDs, the majority of antidepressants, tamoxifen and more.
Advanta Analytical Laboratories offers a variety of testing options in the emerging
field of Pharmacogenetics. Panels have been designed based upon medical
specialty to include genes most commonly involved in the metabolism of
medications prescribed by that specialty. Not only do these tailored panels provide
metabolization predictors, but can also provide physicians with potential toxicity
implications, unwanted drug-drug interactions, and medication sensitivity.
The following table describes the panels currently offered:

TESTING PANELS
COMPREHENSIVE
TESTING MENU

CARDIOLOGY
TESTING PANEL

PAIN MANAGEMENT
TESTING PANEL

PSYCHIATRIC
TESTING PANEL

CYP450 2D6

CYP450 2D6

CYP450 2D6

CYP450 2D6

CYP450 2C9-VKORC1

CYP450 2C9-VKORC1

CYP450 2C9-VKORC1

CYP450 2C9-VKORC1

CYP450 2C19

CYP450 2C19

CYP450 2C19

CYP450 2C19

CYP450 3A4

CYP450 3A4

CYP450 3A4

CYP450 3A4

CYP450 3A5

CYP450 3A5

CYP450 3A5

CYP450 3A5

Factor II Plus-V & MTHFR

Factor II Plus-V & MTHFR

The PROCESS

PHARMACOGENETIC
TESTING ADVANTAGE

Complete the New Physician Registration Form for Advanta Analytical Laboratories,
and we will overnight your Advanta PGx Implementation Kit. Your kit will contain
collection and shipping instructions, swabs, tubules, specimen bags, requisitions
shipping bags and prepaid return shipping labels.
Our highly complex CLIA and COLA accredited and CAP approved laboratory will
cross reference the DNA information through an extensive database of medications
and report results within 72 hrs. The report will provide medication and dosing
guidance for your patient. A cytogenetisist will be available at all times for
questions regarding patient results.
Swab sample is sent to
Advanta Labs to be tested.

Determine patients genotype by

collecting an oral swab sample.

Data from test is generated,

analyzed, and returned to physician.

Pharmacogenetic test is
carefully run on specimen.

PHARMACOGENETIC
TESTING ADVANTAGE

The LEADERS

OWATHA TOOTIE TATUM, PH.D.

BRIAN L. ROBBINS, PH.D.

L A B O R AT O R Y D I R E C T O R

CHIEF SCIENTIFIC OFFICER

Owatha Tootie Tatum joined Advanta Toxicology as the

Laboratory Director in August 2015. Dr. Tatum founded the
Texas Tech University Health Sciences Center Laboratory for
Molecular Diagnostics and served as Associate Professor
in the Departments of Laboratory Medicine and Pathology
(2002-2011). She was instrumental in the development
of Pathogenius Laboratories and served as the Laboratory
Director from its inception (2008-2011). She was also the
Director of Project Management for the Joint Genome Institute
at Lawrence Berkeley National Laboratory, a massive-scale
genome sequencing facility that grew out of the Human
Genome Project.

Dr. Robbins is a motivated hard working laboratorian with a

Ph.D. in Biochemistry from the University of North Dakota. He
has over 25 years of post-graduate experience in the sciences.
This ranges from 12 years in laboratory management in CAP/
CLIA environments to conducting research on the bench and
developing high complexity urine, plasma and intracellular
assays. He completed post-doctoral work at St. Jude Childrens
Research Hospital and stayed on conducting 20 years of
research in HIV drug metabolism and assay development
using HPLC, RIA and LC-MS/MS techniques. Furthering his
carrier by joining University of Nebraska Medical Center, Dr.
Robbins was instrumental in the design and establishment
of the UNMC Antiviral Pharmacology Laboratory while
progressing his work in HIV research developing plasma and
intracellular drug assays.

Dr. Tatum is board certified as a high-complexity laboratory

director and as a clinical consultant in molecular diagnostics.
She also serves as a voting member on the American Board of
Bioanalysis (2013-2016), as well as a CAP specialty inspector
in molecular diagnostics and team leader.

10

His most recent work has involved developing and validating

multi-drug LC-MS/MS assays in urine for pain management
as he continues other scientific and method development
activity at Advanta Analytical Laboratories.

Why ADVANTA

SOLUTIONS, PRODUCTS, & SERVICE

HUMAN ADVANTAGE

LOOKING FOR ANOTHER TEST?

CLIA/COLA
ACCREDITED

We also offer full service laboratory testing for:

CAP APPROVED

MOLECULAR TESTING
COMPREHENSIVE TOXICOLOGY
WOMENS HEALTH CLINICAL TESTING

HOW WE COLLABORATE

At Advanta, we value the opportunity to join forces.

Together, we can configure the best solution for improving your
laboratory testing endeavor. Services that we provide include:

CONSULTING

LAB & HOSPITAL JOINT VENTURES

DEVELOPMENT

PROJECT MANAGEMENT

REFERENCE SERVICES (PRIVATE LABEL)

Call 903.707.2197 or visit www.aalabs.com for more information.
11

CONTACT US
FOR

M OR E

I NFO

ADVANTA CUSTOMER SERVICE

Phone: 903.707.2197
ADVANTA ANALYTICAL LABORATORIES
10935 CR 159
Tyler, TX 75703

Phone: 903.805.9955
Fax: 903.839.2494
advanta@aalabs.com
www.aalabs.com

Advanta Analytical
Laboratories

@Advanta_Labs

/advantalabs

@advantalabs

KIRT PRIMEAUX
BUSINESS DEVELOPMENT

Advanta Analytical Laboratories

10935 CR 159, Tyler, TX 75703
903.805.9955
713.885.6211
kprimeaux@aalabs.com

www.aalabs.com